Events & Presentations

Add Files Arbutus Biopharma Corporate Overview 1.8 MB	Add Files Arbutus Biopharma Corporate Overview 1.8 MB

Archived Events

Summary Toggle May 05,2021 8:45 AM EDT	Arbutus Biopharma Corporation 2021 First Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle May 05 - 06,2021	Chronic Hepatitis B Drug Development Summit Supporting Materials An RNAi for the Treatment O f Chronic Hepatitis B Infection: Clinical Update 1.7 MB
Summary Toggle Mar 09 - 10,2021	H.C. Wainwright Global Life Sciences Conference Listen to webcast
Summary Toggle Mar 04,2021 8:45 AM EST	Arbutus Biopharma Corporation Fourth Quarter and Year End 2020 Financial Results and Corporate Update Listen to webcast Supporting Materials Presentation 1 MB
Summary Toggle Feb 04 - 06,2021	The Asian Pacific Association for the Study of the Liver (APASL) Supporting Materials AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021 311.3 KB
Summary Toggle Jan 11 - 14,2021	H.C. Wainwright BioConnect 2021 Conference Listen to webcast
Summary Toggle Nov 17,2020 12:35 PM EST	Jefferies Virtual London Healthcare Conference Listen to webcast
Summary Toggle Nov 16,2020 8:00 AM EST	AB-729 Clinical Update Click here for webcast Supporting Materials Presentation 802.3 KB
Summary Toggle Nov 15,2020	The Liver Meeting Digital Experience™ \| AASLD Supporting Materials Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection 1.3 MB
Summary Toggle Nov 05,2020 8:45 AM EST	Arbutus Biopharma Corporation 2020 Third Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Oct 20,2020 10:00 AM EDT	H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference Listen to webcast
Summary Toggle Oct 05,2020 1:00 PM EDT	Chardan Virtual 4th Annual Genetic Medicines Conference Listen to webcast
Summary Toggle Sep 28 - 30,2020	International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Virtual Meeting Supporting Materials Impact of the hepatitis B virus (HBV) capsid inhibitor, AB-506, on the single dose pharmacokinetics (PK) of a combined oral contraceptive (COC) 242 KB Evaluation of relationships between AB-506 related ALT elevations and AB-506 pharmacokinetics (PK), metabolite concentrations and plasma bile acids 1.3 MB
Summary Toggle Sep 15,2020 10:30 AM EDT	H.C. Wainwright 22nd Annual Global Investment Conference Listen to webcast
Summary Toggle Aug 29,2020	EASL 2020 Supporting Materials Hepatitis B Virus Core Protein Variants Observed In a First-In-Human Placebo-Controlled Study of a Capsid Inhibitor 709.6 KB
Summary Toggle Aug 12,2020 3:30 PM EDT	Wedbush PacGrow Healthcare Virtual Conference Listen to webcast
Summary Toggle Aug 07,2020 8:45 AM EDT	Arbutus Biopharma Corporation 2020 Second Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Jun 03,2020 1:30 PM EDT	Jefferies Virtual Healthcare Conference Listen to webcast
Summary Toggle May 19,2020 11:40 AM EDT	UBS Virtual Global Healthcare Conference Listen to webcast
Summary Toggle May 18,2020 4:30 PM EDT	AB-729 Clinical Update Listen to webcast Supporting Materials Presentation 593.9 KB
Summary Toggle May 11,2020 8:00 AM EDT	Arbutus Biopharma Corporation 2020 First Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Mar 26,2020 4:30 PM EDT	AB-729 Clinical Update Listen to webcast Supporting Materials Presentation 694.9 KB
Summary Toggle Mar 05,2020 8:45 AM EST	Arbutus Biopharma Corporation Fourth Quarter and Year End 2019 Financial Results and Corporate Update Listen to webcast
Summary Toggle Dec 12,2019	HepDART 2019 Supporting Materials Poster: Key findings leading to the discontinuation of a Capsid Inhibitor (CI), AB-506, in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 844.4 KB Presentation: Key findings leading to the discontinuation of a Capsid Inhibitor (CI), AB-506, in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 992.3 KB
Summary Toggle Nov 11,2019	AASLD 2019 Supporting Materials A Novel HBV Capsid Inhibitor Compound Series Demonstrates Improved Inhibition of HBV WT, T33N and I105T Core Protein Variants and Shows a Unique Binding Mode to Core Protein 9.8 MB Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Inhibitor (CI) AB-506 in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 667.8 KB
Summary Toggle Oct 01 - 05,2019	International HBV Meeting 2019 Supporting Materials Cellular RNA Quality Control Functions Regulate Hepatitis B Virus RNA Steady-State Levels 683.5 KB
Summary Toggle Aug 13,2019 10:55 AM EDT	2019 Wedbush PacGrow Healthcare Conference
Summary Toggle Oct 03 - 06,2018	International HBV Meeting Supporting Materials Mode of action studies on HBV RNA destabilizer AB-452 1.3 MB
Summary Toggle Sep 25,2018	Antivirals: Targeting HBV and Beyond Supporting Materials View Presentation 2.7 MB
Summary Toggle Apr 12,2018	EASL 2018 Supporting Materials Durable inhibition of hepatitis B virus replication and antigenemia using subcutaneously administered siRNA agent AB-729 in preclinical models 1.5 MB Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection AB-506 a next generation HBV capsid inhibitor and AB-452 an HBV RNA destabilizer 1.3 MB

Events & Presentations

Presentations

Upcoming Events

Archived Events

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials